Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMNN-001 + BEV + NACT in Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05739981Phase 2Recruiting
- Sponsor
- Imunon, Inc.
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IMNN-001 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Imunon, Inc. Primary endpoint: Minimal Residual Disease at 8 months. Started Feb 2023; status: recruiting.
02
Drugs
IMNN-001
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05739981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739981.